The longitudinal trajectory of CSF sTREM2: the alzheimer’s disease neuroimaging initiative

Table 3 Interaction effect analysis of age and covariates, sex and covariates in CSF sTREM2 using longitudinal data, ADNI cohort, United States and Canada, 2004–2021

Interaction term	Age × covariates^a		Sex × covariates^a
Interaction term	β (95% CI)	P value	β (95% CI)	P value
Sex (Women)	-0.006 (-0.061, 0.049)	0.830	-	-
Clinical cognitive status
CN	Ref		Ref
MCI	-0.009 (-0.060, 0.042)	0.725	0.066 (-0.044, 0.176)	0.241
Dementia	-0.012 (-0.077, 0.053)	0.722	0.025 (-0.106, 0.156)	0.711
AOPE ε4 allele status^b
AOPE ε4 non-carrier	Ref		Ref
AOPE ε4 heterozygote	-0.039 (-0.098, 0.020)	0.201	0.159 (0.030, 0.288)	0.016
AOPE ε4 homozygote	-0.057 (-0.155, 0.041)	0.252	0.207 (0.001, 0.413)	0.049
The ATN classification^c
A + T-	Ref		Ref
A-T-	-0.087 (-0.171, -0.003)	0.043	0.017 (-0.169, 0.203)	0.860
A-T+	-0.105 (-0.191, -0.019)	0.016	0.128 (-0.068, 0.324)	0.203
A + T+	-0.121 (-0.197, -0.045)	0.002	0.107 (-0.065, 0.279)	0.223
Educational attainment (years)	-0.008 (-0.018, 0.002)	0.106	0.024 (0.00, 0.048)	0.041
CSF Aβ₁₋₄₂	0.014 (-0.031, 0.059)	0.545	0.044 (-0.056, 0.144)	0.387
CSF t-Tau	-0.024 (-0.079, 0.031)	0.394	-0.024 (-0.079, 0.031)	0.394
CSF p-Tau	-0.024 (-0.073, 0.025)	0.338	0.034 (-0.074, 0.142)	0.538
The p-Tau/Aβ₁₋₄₂ ratio	-0.719 (-1.521, 0.083)	0.079	-0.808 (-2.462, 0.846)	0.339

^aModels adjusted for age, sex, race/ethnicity, education levels, TREM2 rare variant carrying status, APOE ε4 allele status, smoking status, marital status, and clinical cognitive status as fixed effects with an additional random slope and intercept for age
^bAPOE ε4 allele status: AOPE ε4 non-carrier, APOE ε2/ε2 or APOE ε2/ε3 or APOE ε3/ε2 or APOE ε3/ε3; AOPE ε4 heterozygote, APOE ε3/ε4 or APOE ε2/ε4; AOPE ε4 homozygote, APOE ε4/ε4
^cThe ATN classification: The ATN classification system included 3 biomarker subgroups: “A” as Aβ aggregation, “T” as tauopathy, and “N” as neurodegeneration. Aβ-positive (A+) participants were those with CSF Aβ₁₋₄₂ levels < 976.6 pg/ml. Tau-positive (T+) participants referred to those who had a p-Tau > 21.8 pg/ml. Neurodegenerative-positive (N+) individuals were those with t-Tau > 245 pg/ml
Abbreviations CN, cognitively normal; MCI, mild cognitive impairment; CSF, cerebrospinal fluid; Aβ₁₋₄₂, amyloid-β1–42; t-Tau, total tau; p-Tau, phosphorylated tau_{181 − p}; sTREM2, soluble TREM2; β, regression coefficient; CI, confidence interval

ISSN: 1758-9193